Académique Documents
Professionnel Documents
Culture Documents
Reninangiotensinsysteminhibitioninthetreatmentofhypertension
OfficialreprintfromUpToDate
www.uptodate.com2015UpToDate
Reninangiotensinsysteminhibitioninthetreatmentofhypertension
Authors
JohannesFEMann,MD
KarlFHilgers,MD
SectionEditors
GeorgeLBakris,MD
NormanMKaplan,MD
DeputyEditor
JohnPForman,MD,MSc
Alltopicsareupdatedasnewevidencebecomesavailableandourpeerreviewprocessiscomplete.
Literaturereviewcurrentthrough:Jun2015.|Thistopiclastupdated:Oct08,2014.
INTRODUCTIONInhibitorsofthereninangiotensinsystem(RAS),includingangiotensinconvertingenzyme
(ACE)inhibitors,angiotensinIIreceptorblockers(ARBs),anddirectrenininhibitorsarecommonlyusedinthe
treatmentofhypertension.TheroleoftheRASinhypertensionandtheuseofspecificinhibitorsofthissystemto
treathypertensionwillbereviewedhere.
TheuseofRASinhibitorsinpatientswithkidneydiseaseanddiabetesarediscussedseparately.(See"Choiceof
drugtherapyinprimary(essential)hypertension:Recommendations"and"Antihypertensivetherapyand
progressionofnondiabeticchronickidneydiseaseinadults"and"Treatmentofhypertensioninpatientswith
diabetesmellitus"and"Treatmentofdiabeticnephropathy".)
Theimportanceoflocal(ie,tissue)RASactivityinlowreninhypertensionandtheeffectsofangiotensinIIonthe
heartarepresentedelsewhere.(See"Lowreninprimary(essential)hypertension"and"ActionsofangiotensinIIon
theheart".)
ANGIOTENSINCONVERTINGENZYMEINHIBITORSSincetheintroductionofcaptoprilin1977[1],
angiotensinconvertingenzyme(ACE)inhibitorshavebecomewidelyusedforthetreatmentofhypertensionand
threeofitsmajorcomplications:acutemyocardialinfarction[2],congestiveheartfailure[3],andchronickidney
disease.Fiftyto60percentofCaucasianpatientshaveagoodresponsetomonotherapywithACEinhibitors,a
responseratesimilartootherfirstlineantihypertensivedrugs[4].ACEinhibitorshavetheadditionaladvantagesof
havingamorefavorablesideeffectprofilethansympatheticblockers,betablockers,anddiuretics[5],andof
producingmoreregressionofleftventricularhypertrophythanbetablockers[6].(See"Clinicalimplicationsand
treatmentofleftventricularhypertrophyinhypertension",sectionon'Choiceofdrugs'.)
Guidelinesissuedin2009bytheEuropeanSocietyofHypertension[7],andin2011byNICE(NationalInstitute
forHealthandClinicalExcellenceofGreatBritain)[8],recommendtheuseofanACEinhibitororangiotensinII
receptorblocker(ARB)inyoungerandnonblackpatients[9].However,thisrecommendationisbasedupon
relativelysmallcrossovertrials[10].
SpecificindicationsforuseThereareanumberofsettingsinwhichACEinhibitorsaretheantihypertensive
drugsofchoicebecauseofpossiblebenefitsinadditiontoloweringthebloodpressure.(See"Choiceofdrug
therapyinprimary(essential)hypertension:Recommendations",sectionon'Indicationsforspecificdrugs'.)
Theseinclude:
Heartfailurewithreducedejectionfraction(HFrEF)[3].(See"ACEinhibitorsinheartfailureduetosystolic
dysfunction:Therapeuticuse"and"Useofbetablockersandivabradineinheartfailurewithreducedejection
fraction"and"Useofdiureticsinpatientswithheartfailure"and"Useofmineralocorticoidreceptor
antagonistsinsystolicheartfailure".)
Proteinuricchronickidneydisease,bothdiabeticandnondiabetic[11].(See"Antihypertensivetherapyand
progressionofnondiabeticchronickidneydiseaseinadults"and"Moderatelyincreasedalbuminuria
(microalbuminuria)intype1diabetesmellitus"and"Moderatelyincreasedalbuminuria(microalbuminuria)in
type2diabetesmellitus"and"Treatmentofhypertensioninpatientswithdiabetesmellitus".)
http://www.uptodate.com/contents/reninangiotensinsysteminhibitioninthetreatmentofhypertension?topicKey=NEPH%2F3815&elapsedTimeMs=4&sour
1/13
14/7/2015
Reninangiotensinsysteminhibitioninthetreatmentofhypertension
Afteramyocardialinfarctioninmostpatients,particularlythosewithheartfailureorreducedsystolicfunction
[2].(See"Angiotensinconvertingenzymeinhibitorsandreceptorblockersinacutemyocardialinfarction:
Recommendationsforuse".)
AntihypertensiveresponseThedeclineinbloodpressureseenwithACEinhibitorsappearstobeprimarilydue
todecreasedformationofangiotensinII,butdecreaseddegradationofkininscouldcontributebybothdirect
vasodilationandincreasingtheproductionofvasodilatorprostaglandins[12].
BlackpatientsmaybelesssensitivethanwhitepatientstoACEinhibitorsasmonotherapyforhypertension(figure
1)[13].AlthoughACEinhibitorsarerelativelyineffectiveasmonotherapyinblacks,theadditionofevenalow
doseofathiazidediuretictoanACEinhibitorleadstoafallinbloodpressurethatiscomparabletothatseenin
whitepatients[14].(See"Treatmentofhypertensioninblacks".)
TheutilityofACEinhibitorswithdiureticsisnotlimitedtoblackpatientssincethesedrugshaveasynergistic
effect,attaininggoalbloodpressureinupto85percentofpatientswithmildhypertension[14].The
antihypertensiveresponsetodiureticsisoftenlimitedbythehypovolemiainducedincreaseinreninreleaseand
subsequentangiotensinIIproduction[15]thiseffectispreventedbyconvertingenzymeinhibition,leadingtoa
moreprominentreductioninbloodpressure.(See"Useofthiazidediureticsinpatientswithprimary(essential)
hypertension".)Forsimilarreasons,dietarysodiumrestrictioncanalsoenhancetheresponsetoanACEinhibitor
[16].(See"Saltintake,saltrestriction,andprimary(essential)hypertension",sectionon'Responseto
antihypertensivedrugs'.)
ACEinhibitorsminimizesomeofthemetabolicchangesinducedbydiuretictherapy.Hypokalemia,forexample,is
lessprominentbecausethereductioninangiotensinIIformationinducedbytheACEinhibitorleadstodecreased
secretionofaldosterone.ACEinhibitorsalsodonotinduceglucoseintolerance,hyperlipidemia,orhyperuricemia,
mayincreaseinsulinsensitivity,andmayminimizeorpreventdiureticinducedelevationsinserumglucose,
cholesterolanduricacidlevels[17].
Apartfromdiuretics,calciumchannelblockerscanbeusedeffectivelywithACEinhibitors,and,asshowninthe
ACCOMPLISHtrial,mayhaveclinicaladvantagesoverdiureticswhenachievedbloodpressureissimilar.
CombinationofanACEinhibitorwithabetablockermaybelessusefulbecauseofinferiorantihypertensive
activitycomparedwithotherACEinhibitorcombinations[18].Thisrelativelackofefficacymaybedueinpartto
similarmechanismsofaction,asangiotensinIIformationandreninsecretionarerespectivelyreduced.(See
"Choiceofdrugtherapyinprimary(essential)hypertension:Recommendations",sectionon'ACCOMPLISHtrial'.)
DoseAswithotherantihypertensiveagents,properdosecanminimizetheincidenceofsideeffects(table1).
TominimizetheriskoffirstdosehypotensionduetoanabruptdeclineinangiotensinIIlevels,thepatientshould
notbevolumedepleted.Theinitialdosecanbereducedbyonehalfinelderlypatientsorthosewithheartfailure
whoareathigherriskforhypotension.SideeffectsotherthanthoserelatedtohypotensioncanoccurwithACE
inhibitors,themostcommonbeingcough[19],lesscommonlyhyperkalemia,andrarelyangioedema[20].ACE
inhibitorsarecontraindicatedduringpregnancy[21].(See"Majorsideeffectsofangiotensinconvertingenzyme
inhibitorsandangiotensinIIreceptorblockers".)
ThedurationofactionvarieswithdifferentACEinhibitors.SomeACEinhibitorscanbegivenoncedaily(eg,
trandolapril,lisinopril,andbenazepril).Theuseoflongeractingagentsoncedailyshouldimprovepatient
compliance,reducecosts,maintainsmoothercontrol,andensurethattheabruptriseinpressureuponawakening
intheearlymorningisblunted,hopefullytherebyreducingtheincidenceofseriouscardiovasculareventsatthis
time.
Aftertheinitiationoftherapy,thepatientshouldbereexaminedinafewweekstoallowthefullantihypertensive
effecttooccur.Ifthereisnoorlittlefallinbloodpressurewithanadequatedose,thedrugcanbestoppedand
differentclassofdrugstarted,aconceptcalled"sequentialmonotherapy."Alternatively,anotherdrugmaybe
added,suchasacalciumchannelblocker.(See"Choiceofdrugtherapyinprimary(essential)hypertension:
Recommendations",sectionon'Sequentialmonotherapy'.)
http://www.uptodate.com/contents/reninangiotensinsysteminhibitioninthetreatmentofhypertension?topicKey=NEPH%2F3815&elapsedTimeMs=4&sour
2/13
14/7/2015
Reninangiotensinsysteminhibitioninthetreatmentofhypertension
Ifthepatient'sbloodpressureisreducedbytheACEinhibitorbutthegoalpressureisnotachieved,thedosecan
begraduallyincreasedtothemaximumlevelsnotedinthetable(table1).However,theadditionofaseconddrug
fromadifferentclasswillprovidemuchgreaterantihypertensiveeffect[22].
Inpatientswithextensiveatherosclerosisorrenalinsufficiencywhoaremorelikelytohaverenovascular
stenoses,arepeatplasmacreatinineconcentrationshouldbeobtainedwithinonetotwoweekstoensurethat
renalperfusionhasbeenmaintained.However,amodestandnonprogressiveincreaseintheplasmacreatininein
suchpatientsshouldnotpromptdiscontinuationoftherapy.(See"RenaleffectsofACEinhibitorsin
hypertension",sectionon'Renovascularhypertension'.)
ANGIOTENSINIIRECEPTORBLOCKERSAngiotensinIIreceptorblockers(ARBs)interferewiththerenin
angiotensinsystembyimpairingthebindingofangiotensinIItotheAT1receptoronthecellmembrane,thereby
inhibitingtheactionofangiotensinII[23].BlockadeoftheactionofangiotensinIIleadstoelevationsinplasma
levelsofrenin,angiotensinI,andangiotensinII.However,thisbuildupofprecursorsdoesnotoverwhelmthe
receptorblockade,asevidencedbyapersistentfallinbothbloodpressureandplasmaaldosteronelevels[24].
DifferencesbetweenACEinhibitorsandARBsTherearesubstantialpharmacologicaldifferencesinthe
actionsofangiotensinconvertingenzyme(ACE)inhibitorsandARBs,butfewclinicaldifferenceshavebeen
documented.Atleastthreefactorsmaycontributetothepharmacologicaldifferences(figure2):
Angiotensinconvertingenzymeisakininase.Thus,inhibitingthisenzyme,whichnormallydegrades
bradykinin,withanACEinhibitorleadstoincreasedkininlevels,aneffectnotseenwithanARB.Thisis
likelyresponsibleforthecoughthatmaybeseenwithACEinhibitors(butnotwithARBs),althoughhigh
bradykininlevelsmayalsoprovideadditionalvasodilationandotherbenefitsnotobservedwithARBs.
BydecreasingangiotensinIIproduction,ACEinhibitorsreducetheeffectofbothAT1andAT2receptors
onlytheformerareinhibitedbytheARBs.
Intheheart,kidney,andperhapsthebloodvessels,theproductionofangiotensinIImaybecatalyzedby
enzymesotherthanangiotensinconvertingenzyme,suchaschymase[25].TheeffectoftheangiotensinII
producedbythisreactioncanbeinhibitedbytheARBsbutnotbyACEinhibitors.However,theroleofthese
nonACEenzymesforthegenerationofangiotensinIIinvivo,ifany,isuncertain.
EfficacyanddoseTheARBshaveaneffectsimilartothatseenwithmonotherapywithotherantihypertensive
drugs(table1)[26].However,severalstudieshaveshownthatlosartan,whengivenoncedaily,doesnotcontrol
bloodpressuretothesamemagnitudeasotherARBs(irbesartan,telmisartan,candesartan,andvalsartan)[2730].
Ontheotherhand,losartanproducesaslightfallinplasmauricacidthatdoesnotoccurwiththeotherARBs,an
effectthatisduetoenhanceduricacidexcretion[31].Thisappearstobemediatedatleastinpartbydirect
inhibitionoftheproximalurateanionexchangerthatisresponsibleforuratereabsorption[32].
TheantihypertensiveefficacyofARBsappearstoberoughlyequivalenttothatoftheACEinhibitors.Ameta
analysisof61studiesthatdirectlycomparedangiotensinIIreceptorblockersandACEinhibitorsreportedno
differenceintheantihypertensiveeffectsoftheseagents[26].
Inaddition,theeffectsofARBsandACEinhibitorsoncardiovasculareventsappearsimilar.TheONTARGETtrial
comparedtelmisartan(80mg/day),ramipril(10mg/day),andcombinationtherapy(80+10mg/day)withboth
agentsin25,620patientswithvasculardiseaseordiabetes[33].Theprimaryoutcomewasdeathfrom
cardiovascularcauses,myocardialinfarction,stroke,orhospitalizationforheartfailure.Achievedmeanblood
pressurewaslowerinpatientswhoreceivedtelmisartancomparedwithramipril(by0.9/0.6mmHg)andinpatients
whoreceivedbothagentscomparedwithramipril(2.4/1.4mmHg).Thecardiovascularoutcomesweresimilarinall
threegroups,whilecoughwasmorecommonwithramiprilandbothhyperkalemiaandacutekidneyinjurywere
morecommonwithcombinedtherapy.(See"Majorsideeffectsofangiotensinconvertingenzymeinhibitorsand
angiotensinIIreceptorblockers".)
Inaddition,ametaanalysisofninetrialsand11,007patientsthatdirectlycomparedACEinhibitorswithARBsin
http://www.uptodate.com/contents/reninangiotensinsysteminhibitioninthetreatmentofhypertension?topicKey=NEPH%2F3815&elapsedTimeMs=4&sour
3/13
14/7/2015
Reninangiotensinsysteminhibitioninthetreatmentofhypertension
hypertensivepatientsfoundsimilarratesofallcausemortalityandcardiovascularmortality[34].Incontrast,drug
withdrawalduetoadverseeventswassignificantlymorefrequentwithACEinhibitors(oneadditionalwithdrawal
fromtherapyforevery55patientstreatedwithACEinhibitorsoverfouryears),mostlyduetodrycough.Thus,
ARBsareareasonablealternativetoACEinhibitortherapyinhypertensivepatients.
Aswithotheragentsthatinhibitthereninangiotensinsystem,theefficacyofARBsisenhancedbyconcomitant
administrationoflowdosesofadiuretic[35],andbyareductionindietarysodiumintake.AswithACEinhibitors,
ARBsappeartominimizethehypokalemiaandhyperuricemiainducedbydiuretictherapy[35].(See"Saltintake,
saltrestriction,andprimary(essential)hypertension",sectionon'Responsetoantihypertensivedrugs'.)
SIDEEFFECTSBothangiotensinconvertingenzyme(ACE)inhibitorsandangiotensinIIreceptorblockers
(ARBs)aregenerallywelltolerated.CoughandangioedemaarelesscommonwithARBs[33].BothACE
inhibitorsandARBsarecontraindicatedinpregnancy.Theseissuesarediscussedindetailseparately.(See
"MajorsideeffectsofangiotensinconvertingenzymeinhibitorsandangiotensinIIreceptorblockers"and
"Angiotensinconvertingenzymeinhibitorsandreceptorblockersinpregnancy".)
ACEinhibitorsplusARBsAseparateissueisthesideeffectsassociatedwithcombinedACEinhibitor/ARB
therapycomparedwitheitherdrugalone.TheONTARGETtrialcitedaboveofhighriskpatients[33,36]founda
significantincreaseinadverseeffects(includingapossibleincreaseinmortality)withcombinedtherapycompared
withanACEinhibitoralone.Asaresult,combinedtherapyisnotrecommendedforthetreatmentofhypertension.
Thedatasupportingadverseeffectsandthepossibleroleofcombinedtherapytoslowprogressioninpatientswith
proteinuricchronickidneydiseasearediscussedelsewhere.(See"Majorsideeffectsofangiotensinconverting
enzymeinhibitorsandangiotensinIIreceptorblockers",sectionon'CombinationofACEinhibitorsandARBs'and
"Antihypertensivetherapyandprogressionofnondiabeticchronickidneydiseaseinadults",sectionon
'CombinationofACEinhibitorsandARBs'.)
DIRECTRENININHIBITORSThefirsteffectiveoraldirectrenininhibitor,aliskiren,becameavailableinthe
UnitedStatesinMarch2007.Aliskirenlowersbloodpressuretoadegreecomparabletomostotheragents[37].A
numberofstudieshaveevaluatedthebloodpressureloweringeffectofaliskirenincombinationwithother
antihypertensivedrugs[3740].Inonereport,thecombinationofmaximumdosesofaliskirenandvalsartan
decreasedbloodpressuremorethanmaximumdosesofeitheragentalonebutnotmorethanwouldbeexpected
withdualtherapyusingdrugsfromdifferentclasses[41].Aliskiren,aswithotherinhibitorsofthereninangiotensin
system,shouldnotbeusedinpregnancy.
IntheAVOIDtrial,aliskirenpluslosartanwasassociatedwithasignificant20percentgreaterreductionin
proteinuriacomparedwithlosartanaloneinpatientswithtype2diabetesandnephropathy,intheabsenceofa
significantlygreatereffectonbloodpressure[42].However,thiseffectonproteinuriadidnottranslateintoa
clinicalbenefit.IntheALTITUDEtrial,8600patientswithtype2diabetesandkidneydiseasealreadytakingeither
anangiotensinconvertingenzyme(ACE)inhibitororangiotensinIIreceptorblocker(ARB)wererandomlyassigned
toadditionaltherapywithaliskirenorplacebo[43].TheALTITUDEtrialwasstoppedearlybecauseoffutility(no
benefitontheprimarycardiovascularandrenaloutcomes)andbecausealiskirentherapyproduceda
nonsignificantlyhigherrateofadverseevents(ie,nonfatalstroke,hypotension).TheALTITUDEtrialisdiscussed
indetailelsewhere.(See"Treatmentofdiabeticnephropathy",sectionon'Aliskirenplusangiotensininhibition'.)
Theeffectofaliskirenonprogressionofatheroscleroticcoronaryarterydiseaseinpatientswithcontrolled
hypertensionwasexaminedintheAliskirenQuantitativeAtherosclerosisRegressionIntravascularUltrasound
Study(AQUARIUS)[44].Inthistrial,613patientswithasystolicbloodpressurebetween125and139mmHg
(mostofwhomweretreatedwithantihypertensivemedications)andtwoothercardiovascularriskfactorswere
randomlyassignedtoaliskiren(300mg/day)orplacebo.After18months,theatheroscleroticburdenand
progressionofatherosclerosis(measuredbycoronaryintravascularultrasound)wassimilarbetweenthegroups.In
asecondaryanalysisbaseduponasmallnumberofevents,aliskirenappearedtoreducetherateof
cardiovascularevents.However,thisanalysisexcludeddiabeticpatientswhoweretreatedwithangiotensin
inhibitors(approximately15percentofthestudypopulation),assuchpatientswereremovedfromthestudyafter
http://www.uptodate.com/contents/reninangiotensinsysteminhibitioninthetreatmentofhypertension?topicKey=NEPH%2F3815&elapsedTimeMs=4&sour
4/13
14/7/2015
Reninangiotensinsysteminhibitioninthetreatmentofhypertension
publicationoftheALTITUDEtrial[45].Inaddition,adverseeventsweremorecommonwithaliskiren.
AnincreasedriskofhyperkalemiawhenaliskireniscombinedwithACEinhibitorsorARBshasbeendescribedin
theALTITUDEtrialandinotherstudies[43,46].Thus,aliskirenshouldnotbecombinedwithACEinhibitorsor
ARBs[47].
SUMMARYANDRECOMMENDATIONS
Inhibitorsofthereninangiotensinsystem,includingangiotensinconvertingenzyme(ACE)inhibitors,
angiotensinIIreceptorblockers(ARBs),anddirectrenininhibitorsarecommonlyusedinthetreatmentof
hypertension.(See'Introduction'above.)
ThereareanumberofsettingsinwhichACEinhibitorsaretheantihypertensivedrugsofchoicebecauseof
possiblebenefitsinadditiontoloweringthebloodpressure(see'Specificindicationsforuse'above):
Heartfailurewithreducedejectionfraction(HFrEF)
Proteinuricchronickidneydisease,bothdiabeticandnondiabetic
Afteramyocardialinfarctioninmostpatients,particularlythosewithheartfailureorreducedsystolic
function
ProperdoseofACEinhibitorscanminimizetheincidenceofsideeffects(table1).Thedurationofaction
varieswithdifferentACEinhibitors.SomeACEinhibitorscanbegivenoncedaily(eg,trandolapril,lisinopril,
andbenazepril).(See'Dose'above.)
TherearepharmacologicaldifferencesintheactionsofACEinhibitorsandARBs.Exceptforthecough
associatedwithACEinhibitors,thesepharmacologicaldifferencesarenotassociatedwithclinically
meaningfuldifferencesintherapeuticeffects.Atleastthreefactorsmaycontributetothepharmacological
differences(figure2)(see'DifferencesbetweenACEinhibitorsandARBs'above):
Angiotensinconvertingenzymeisakininase.Thus,inhibitingthisenzyme,whichnormallydegrades
bradykinin,withanACEinhibitorleadstoincreasedkininlevels,aneffectnotseenwithanARB.This
islikelyresponsibleforthecoughthatmaybeseenwithACEinhibitors(butnotwithARBs),although
highbradykininlevelsmayalsoprovideadditionalvasodilationandotherbenefitsnotobservedwith
ARBs.
BydecreasingangiotensinIIproduction,ACEinhibitorsreducetheeffectofbothAT1andAT2
receptorsonlytheformerareinhibitedbytheARBs.
Intheheart,kidney,andperhapsthebloodvessels,theproductionofangiotensinIImaybecatalyzed
byenzymesotherthanangiotensinconvertingenzyme,suchaschymase.Theeffectoftheangiotensin
IIproducedbythisreactioncanbeinhibitedbytheARBsbutnotbyACEinhibitors.
TheARBshaveaneffectsimilartothatseenwithmonotherapywithotherantihypertensivedrugs,including
ACEinhibitors(table1).
TheantihypertensiveeffectofbothACEinhibitorsandARBsisenhancedbyconcomitantadministrationof
lowdosesofadiuretic,andbyareductionindietarysodiumintake.Bothdrugsalsoappeartominimizethe
hypokalemiaandhyperuricemiainducedbydiuretictherapy.(See'Dose'aboveand'Efficacyanddose'
aboveand"Saltintake,saltrestriction,andprimary(essential)hypertension",sectionon'Responseto
antihypertensivedrugs'.)
BothACEinhibitorsandARBsaregenerallywelltolerated.Sideeffectsotherthanthoserelatedto
hypotensioncanoccurwithbothdrugs,includinghyperkalemiaandrarelyangioedema,aswellasacute
kidneyinjuryinpatientswithloweffectivearterialbloodvolume(eg,diarrhea,vomiting,andheartfailure).
CoughisacommonsideeffectofACEinhibitors.ACEinhibitorsandARBsarecontraindicatedduring
http://www.uptodate.com/contents/reninangiotensinsysteminhibitioninthetreatmentofhypertension?topicKey=NEPH%2F3815&elapsedTimeMs=4&sour
5/13
14/7/2015
Reninangiotensinsysteminhibitioninthetreatmentofhypertension
pregnancy.(See'Sideeffects'aboveand"Majorsideeffectsofangiotensinconvertingenzymeinhibitorsand
angiotensinIIreceptorblockers".)
CombinedtherapywithbothanACEinhibitorandARBisnotrecommendedforthetreatmentof
hypertension.(See'ACEinhibitorsplusARBs'above.)
Thefirsteffectiveoraldirectrenininhibitor,aliskiren,lowersbloodpressuretoadegreecomparabletomost
otheragents.IncombinationwithanACEinhibitororARB,aliskirenincreasestheriskofadverseeffects
anddoesnotlowertheriskofcardiovascularevent.Thus,aliskirenshouldnotbecombinedwithACE
inhibitorsorARBs.(See'Directrenininhibitors'above.)
UseofUpToDateissubjecttotheSubscriptionandLicenseAgreement.
REFERENCES
1. OndettiMA,RubinB,CushmanDW.Designofspecificinhibitorsofangiotensinconvertingenzyme:new
classoforallyactiveantihypertensiveagents.Science1977196:441.
2. PfefferMA,BraunwaldE,MoyLA,etal.Effectofcaptoprilonmortalityandmorbidityinpatientswithleft
ventriculardysfunctionaftermyocardialinfarction.Resultsofthesurvivalandventricularenlargementtrial.
TheSAVEInvestigators.NEnglJMed1992327:669.
3. Effectofenalaprilonsurvivalinpatientswithreducedleftventricularejectionfractionsandcongestiveheart
failure.TheSOLVDInvestigators.NEnglJMed1991325:293.
4. NeatonJD,GrimmRHJr,PrineasRJ,etal.TreatmentofMildHypertensionStudy.Finalresults.Treatment
ofMildHypertensionStudyResearchGroup.JAMA1993270:713.
5. CroogSH,LevineS,TestaMA,etal.Theeffectsofantihypertensivetherapyonthequalityoflife.NEnglJ
Med1986314:1657.
6. KlingbeilAU,SchneiderM,MartusP,etal.Ametaanalysisoftheeffectsoftreatmentonleftventricular
massinessentialhypertension.AmJMed2003115:41.
7. ManciaG,LaurentS,AgabitiRoseiE,etal.ReappraisalofEuropeanguidelinesonhypertension
management:aEuropeanSocietyofHypertensionTaskForcedocument.JHypertens200927:2121.
8. KrauseT,LovibondK,CaulfieldM,etal.Managementofhypertension:summaryofNICEguidance.BMJ
2011343:d4891.
9. ManciaG,DeBackerG,DominiczakA,etal.2007ESHESCPracticeGuidelinesfortheManagementof
ArterialHypertension:ESHESCTaskForceontheManagementofArterialHypertension.JHypertens
200725:1751.
10. DickersonJE,HingoraniAD,AshbyMJ,etal.Optimisationofantihypertensivetreatmentbycrossover
rotationoffourmajorclasses.Lancet1999353:2008.
11. KidneyDiseaseOutcomesQualityInitiative(K/DOQI).K/DOQIclinicalpracticeguidelinesonhypertension
andantihypertensiveagentsinchronickidneydisease.AmJKidneyDis200443:S1.
12. LinzW,WiemerG,GohlkeP,etal.Contributionofkininstothecardiovascularactionsofangiotensin
convertingenzymeinhibitors.PharmacolRev199547:25.
13. MatersonBJ,RedaDJ,CushmanWC,etal.Singledrugtherapyforhypertensioninmen.Acomparisonof
sixantihypertensiveagentswithplacebo.TheDepartmentofVeteransAffairsCooperativeStudyGroupon
AntihypertensiveAgents.NEnglJMed1993328:914.
14. TownsendRR,HollandOB.Combinationofconvertingenzymeinhibitorwithdiureticforthetreatmentof
hypertension.ArchInternMed1990150:1175.
15. VaughanEDJr,CareyRM,PeachMJ,etal.ThereninresponsetodiuretictherapylAlimitationof
antihypertensivepotential.CircRes197842:376.
16. SlagmanMC,WaandersF,HemmelderMH,etal.Moderatedietarysodiumrestrictionaddedtoangiotensin
convertingenzymeinhibitioncomparedwithdualblockadeinloweringproteinuriaandbloodpressure:
randomisedcontrolledtrial.BMJ2011343:d4366.
17. PollareT,LithellH,BerneC.Acomparisonoftheeffectsofhydrochlorothiazideandcaptoprilonglucose
http://www.uptodate.com/contents/reninangiotensinsysteminhibitioninthetreatmentofhypertension?topicKey=NEPH%2F3815&elapsedTimeMs=4&sour
6/13
14/7/2015
Reninangiotensinsysteminhibitioninthetreatmentofhypertension
andlipidmetabolisminpatientswithhypertension.NEnglJMed1989321:868.
18. PickeringTG.Theuseofangiotensinconvertingenzymeinhibitorsincombinationwithother
antihypertensiveagents.AmJHypertens19914:73S.
19. BangaloreS,KumarS,MesserliFH.Angiotensinconvertingenzymeinhibitorassociatedcough:deceptive
informationfromthePhysicians'DeskReference.AmJMed2010123:1016.
20. BeltramiL,ZanichelliA,ZingaleL,etal.Longtermfollowupof111patientswithangiotensinconverting
enzymeinhibitorrelatedangioedema.JHypertens201129:2273.
21. LiDK,YangC,AndradeS,etal.Maternalexposuretoangiotensinconvertingenzymeinhibitorsinthefirst
trimesterandriskofmalformationsinoffspring:aretrospectivecohortstudy.BMJ2011343:d5931.
22. WaldDS,LawM,MorrisJK,etal.Combinationtherapyversusmonotherapyinreducingbloodpressure:
metaanalysison11,000participantsfrom42trials.AmJMed2009122:290.
23. BurnierM,BrunnerHR.AngiotensinIIreceptorantagonists.Lancet2000355:637.
24. GrossmanE,PelegE,CarrollJ,etal.HemodynamicandhumoraleffectsoftheangiotensinIIantagonist
losartaninessentialhypertension.AmJHypertens19947:1041.
25. HuangXR,ChenWY,TruongLD,LanHY.Chymaseisupregulatedindiabeticnephropathy:implicationsfor
analternativepathwayofangiotensinIImediateddiabeticrenalandvasculardisease.JAmSocNephrol
200314:1738.
26. MatcharDB,McCroryDC,OrlandoLA,etal.Systematicreview:comparativeeffectivenessofangiotensin
convertingenzymeinhibitorsandangiotensinIIreceptorblockersfortreatingessentialhypertension.Ann
InternMed2008148:16.
27. KasslerTaubK,LittlejohnT,ElliottW,etal.ComparativeefficacyoftwoangiotensinIIreceptor
antagonists,irbesartanandlosartaninmildtomoderatehypertension.Irbesartan/LosartanStudy
Investigators.AmJHypertens199811:445.
28. MallionJ,SicheJ,LacourcireY.ABPMcomparisonoftheantihypertensiveprofilesoftheselective
angiotensinIIreceptorantagoniststelmisartanandlosartaninpatientswithmildtomoderatehypertension.J
HumHypertens199913:657.
29. AnderssonOK,NeldamS.Theantihypertensiveeffectandtolerabilityofcandesartancilexetil,anew
generationangiotensinIIantagonist,incomparisonwithlosartan.BloodPress19987:53.
30. HednerT,OparilS,RasmussenK,etal.AcomparisonoftheangiotensinIIantagonistsvalsartanand
losartaninthetreatmentofessentialhypertension.AmJHypertens199912:414.
31. TikkanenI,OmvikP,JensenHA.ComparisonoftheangiotensinIIantagonistlosartanwiththeangiotensin
convertingenzymeinhibitorenalaprilinpatientswithessentialhypertension.JHypertens199513:1343.
32. EnomotoA,KimuraH,ChairoungduaA,etal.Molecularidentificationofarenalurateanionexchangerthat
regulatesblooduratelevels.Nature2002417:447.
33. ONTARGETInvestigators,YusufS,TeoKK,etal.Telmisartan,ramipril,orbothinpatientsathighriskfor
vascularevents.NEnglJMed2008358:1547.
34. LiEC,HeranBS,WrightJM.Angiotensinconvertingenzyme(ACE)inhibitorsversusangiotensinreceptor
blockersforprimaryhypertension.CochraneDatabaseSystRev20148:CD009096.
35. SofferBA,WrightJTJr,PrattJH,etal.Effectsoflosartanonabackgroundofhydrochlorothiazidein
patientswithhypertension.Hypertension199526:112.
36. MannJF,SchmiederRE,McQueenM,etal.Renaloutcomeswithtelmisartan,ramipril,orboth,inpeopleat
highvascularrisk(theONTARGETstudy):amulticentre,randomised,doubleblind,controlledtrial.Lancet
2008372:547.
37. OhBH,MitchellJ,HerronJR,etal.Aliskiren,anoralrenininhibitor,providesdosedependentefficacyand
sustained24hourbloodpressurecontrolinpatientswithhypertension.JAmCollCardiol200749:1157.
38. PoolJL,SchmiederRE,AziziM,etal.Aliskiren,anorallyeffectiverenininhibitor,providesantihypertensive
efficacyaloneandincombinationwithvalsartan.AmJHypertens200720:11.
39. VillamilA,ChrysantSG,CalhounD,etal.Renininhibitionwithaliskirenprovidesadditiveantihypertensive
efficacywhenusedincombinationwithhydrochlorothiazide.JHypertens200725:217.
40. ShafiqMM,MenonDV,VictorRG.Oraldirectrenininhibition:premise,promise,andpotentiallimitationsof
anewantihypertensivedrug.AmJMed2008121:265.
http://www.uptodate.com/contents/reninangiotensinsysteminhibitioninthetreatmentofhypertension?topicKey=NEPH%2F3815&elapsedTimeMs=4&sour
7/13
14/7/2015
Reninangiotensinsysteminhibitioninthetreatmentofhypertension
41. OparilS,YarowsSA,PatelS,etal.Efficacyandsafetyofcombineduseofaliskirenandvalsartanin
patientswithhypertension:arandomised,doubleblindtrial.Lancet2007370:221.
42. ParvingHH,PerssonF,LewisJB,etal.Aliskirencombinedwithlosartanintype2diabetesand
nephropathy.NEnglJMed2008358:2433.
43. ParvingHH,BrennerBM,McMurrayJJ,etal.Cardiorenalendpointsinatrialofaliskirenfortype2
diabetes.NEnglJMed2012367:2204.
44. NichollsSJ,BakrisGL,KasteleinJJ,etal.Effectofaliskirenonprogressionofcoronarydiseaseinpatients
withprehypertension:theAQUARIUSrandomizedclinicaltrial.JAMA2013310:1135.
45. TardifJC,GrgoireJ.Reninangiotensinsysteminhibitionandsecondarycardiovascularprevention.JAMA
2013310:1130.
46. HarelZ,GilbertC,WaldR,etal.Theeffectofcombinationtreatmentwithaliskirenandblockersofthe
reninangiotensinsystemonhyperkalaemiaandacutekidneyinjury:systematicreviewandmetaanalysis.
BMJ2012344:e42.
47. RajagopalanS,BakrisGL,AbrahamWT,etal.Completereninangiotensinaldosteronesystem(RAAS)
blockadeinhighriskpatients:recentinsightsfromreninblockadestudies.Hypertension201362:444.
Topic3815Version11.0
http://www.uptodate.com/contents/reninangiotensinsysteminhibitioninthetreatmentofhypertension?topicKey=NEPH%2F3815&elapsedTimeMs=4&sour
8/13
14/7/2015
Reninangiotensinsysteminhibitioninthetreatmentofhypertension
GRAPHICS
Antihypertensiveresponsetodifferentdrugsinblacks
Responseratestosingledrugtherapyforhypertensioninblacksoverthe
ageof60years.Thehighestresponsewasseenwithdiltiazemand
hydrochlorothiazide(HCTZ)andthelowestwithcaptopril.Aresponsewas
definedasadiastolicpressurebelow90mmHgattheendofthetitration
phaseandbelow95mmHgatoneyear.Thepatternofresponsewas
similarbutthesuccessrateforeachdrugwasreducedby5to15percent
ifgoaldiastolicpressurewerelessthan90mmHgatoneyear.There
werebetween42and53patientsineachgroup.
Datafrom:MatersonBJ,RedaDJ,CushmanWC.DepartmentofveteransAffairs
singledrugtherapyofhypertensionstudy.Revisedfiguresandnewdata.
DepartmentofVeteransAffairsCooperativeStudyGrouponAntihypertensive
Agents.AmJHypertens19958:189.
Graphic65117Version5.0
http://www.uptodate.com/contents/reninangiotensinsysteminhibitioninthetreatmentofhypertension?topicKey=NEPH%2F3815&elapsedTimeMs=4&sour
9/13
14/7/2015
Reninangiotensinsysteminhibitioninthetreatmentofhypertension
Angiotensinconvertingenzyme(ACE)inhibitorsandreceptor
antagonistsfortreatmentofadultswithhypertension
Drug
UStradename
Generic
preparation
availableinUS
Usualoraldaily
doserange
(adult)mg*
ACEinhibitors
Benazepril
Lotensin
Yes
20to80
Captopril
Capoten
Yes
25to150intwoor
(onlyavailableinUS
asgenericpreparation)
Cilazapril
Inhibace
(Canadiantrade
threedivideddoses
No
2.5to5
name)
Enalapril
Vasotec
Yes
10to40
Fosinopril
Monopril
(onlyavailableinUS
asgenericpreparation)
Yes
20to80
Lisinopril
Prinivil ,Zestril
Yes
10to40
Moexipril
Univasc
Yes
7.5to30
Perindopril
Aceon
Yes
4to8
Quinapril
Accupril
Yes
10to40
Ramipril
Altace
Yes
2.5to20
Trandolapril
Mavik
Yes
2to4
AngiotensinIIreceptorantagonists
Azilsartan
Edarbi
No
80
Candesartan
Atacand
No
16to32
Eprosartan
Teveten
Yes
600to800
Ibresartan
Avapro
Yes
150to300
Losartan
Cozaar
Yes
50to100
Olmesartan
Benicar
No
20to40
Telmisartan
Micardis
No
40to80
Valsartan
Diovan
No
80to320
*Thedoserangereferstothetreatmentofpatientswithhypertension.Dosesaslowasonehalforone
quarterthelowerdoseshownmaybeusedinitiallyinhighriskpatientssuchasthosewithheartfailure,
significantrenalinsufficiency,hyponatremia,intravascularvolumedepletion,orreceivingconcurrent
treatmentwithadiuretic.
Thedrugmaybegivenindivideddosesatthehigherdoselevels.Adjustaccordingtobloodpressure
responseatpeakandtroughbloodlevels.
http://www.uptodate.com/contents/reninangiotensinsysteminhibitioninthetreatmentofhypertension?topicKey=NEPH%2F3815&elapsedTimeMs=4&sou
10/13
14/7/2015
Reninangiotensinsysteminhibitioninthetreatmentofhypertension
NotavailableinUS.
Datafrom:LexicompOnline.Copyright19782015Lexicomp,Inc.AllRightsReserved.
Graphic64770Version8.0
http://www.uptodate.com/contents/reninangiotensinsysteminhibitioninthetreatmentofhypertension?topicKey=NEPH%2F3815&elapsedTimeMs=4&sou
11/13
14/7/2015
Reninangiotensinsysteminhibitioninthetreatmentofhypertension
Comparisonoftheactionsofangiotensinconverting
enzymeinhibitorsandangiotensinIIreceptor
blockers
ACE:angiotensinconvertingenzymeACEI:angiotensinconvertingenzyme
inhibitorARB:angiotensinIIreceptorblocker.
Graphic55726Version3.0
http://www.uptodate.com/contents/reninangiotensinsysteminhibitioninthetreatmentofhypertension?topicKey=NEPH%2F3815&elapsedTimeMs=4&sou
12/13
14/7/2015
Reninangiotensinsysteminhibitioninthetreatmentofhypertension
Disclosures
Disclosures:JohannesFEMann,MDGrant/Research/ClinicalTrialSupport:NovoNordisk[Diabetes(Liraglutide)]Vifor[Dialysis(Iron
hydroxide)]Clegene[Dialysis(Sotatercept)].Speaker'sBureau:Amgen[Anemia(Darbepoetin)Roche[Anemia(Methoxypolyethylene
glycolepoetinbeta)Novartis[Hypertension(Valsartan)]Bruan[Dialysis(dialysisdevices)]Fresenius[Dialysis(dialysisdevices)].
Consultant/AdvisoryBoards:NovoNordisk[Diabetes(Liraglutide)]Relypsa[Kbinder(Patiromer)]Abbvie[CKD(Paricalcitol)]Bayer
[Hypertension(Diuretics)].KarlFHilgers,MDGrant/Research/ClinicalTrialSupport:AstellasNovartis[Kidneytransplantation
(Tacrolimus,cyclosporine,everolimus)].GeorgeLBakris,MDGrant/Research/ClinicalTrialSupport:MedtronicRelypsa[Hypertension,
hyperkalemia].Consultant/AdvisoryBoards:MedtronicRelypsaBayerNovartisDSIBoehringerIngelheimLexiconJanssenAstra
ZenecaKona[Diabetes,hyperkalemia,resistanthypertension(Canagliflozin,dapagliflozin,empagliflozin)].NormanMKaplan,MD
Nothingtodisclose.JohnPForman,MD,MScNothingtodisclose.
Contributordisclosuresarereviewedforconflictsofinterestbytheeditorialgroup.Whenfound,theseareaddressedbyvettingthrougha
multilevelreviewprocess,andthroughrequirementsforreferencestobeprovidedtosupportthecontent.Appropriatelyreferenced
contentisrequiredofallauthorsandmustconformtoUpToDatestandardsofevidence.
Conflictofinterestpolicy
http://www.uptodate.com/contents/reninangiotensinsysteminhibitioninthetreatmentofhypertension?topicKey=NEPH%2F3815&elapsedTimeMs=4&sou
13/13